


New approach for the development of candidate reference measurement procedures

C. Swart, J. Gleitzmann, N. Tokman, A. Raab,
E. Del Castillo, C. Brauckmann, S. Zabel,
C.-G. Arsene, C. Frank



EMRP

European Metrology Research Programme
► Programme of EURAMET



The EMRP is jointly funded by the EMRP participating countries within EURAMET and the European Union

Metrology for metalloproteins

- [Home](#)
- [The Project](#)
- [Work Packages](#)
- [The Consortium](#)
- [Publications](#)
- [News & Events](#)
- [Members Area](#)
- [Contact](#)


EMRP Project "Metrology for Metalloproteins" - HLT05



Metalloproteins are especially important in medical diagnosis as they represent around 30 % of the whole proteome. Many of them such as haemoglobin (Hb), transferrin (Tf), superoxide dismutase (SOD) or ceruloplasmin (Cp) are important markers for diseases such as Down's syndrome in the prenatal diagnostic (SOD), inflammation (acute-phase proteins like Tf or C-reactive protein (CRP)) or deficiency diseases (Hb, Tf, Cp). Moreover, they are used for the control of treatment efficiency e.g. total Hb as the most important marker for anaemia treatment. Other metalloproteins are important in cancer treatment like selenoproteins or platinum (Pt) containing drugs that form adducts to biomolecules.


→ Contact

The research leading to these results has received funding from the European Union on the basis of Decision No 912/2009/EC.
Last updated: 2013-10-17



Motivation


IG3/14
Transferrin
Kit 28




HA3/14
Haemoglobin
Kit 70

15 %

Reference institute for bioanalytics
<http://www.dgkl-rfb.de/>



6 %




Example: Ceruloplasmin (CER)

- Cu storage protein
- marker for Wilson's disease - a genetic defect in 1:30 000 to 1:300 000 persons
- if untreated ⇒ liver failure and neurological defects
- methods have to distinguish between functional and non-functional protein forms

¹Infusino I. et al., Anal Bioanal Chem (2010) 397:521-525



Multimodal approach for protein quantification

organic MS
peptide target



ICP-MS
determination of elements


RAMAN




optical methods
fluorescence or emission

Isotope dilution approach

sample x/
reference z




blend bx/bz




mass fraction
 w_x

spike y





- double (inverse) isotope dilution (ID)
no spike calibration
no K factors needed (in most cases)
- exact matching
isotope ratio of blends near unity
equal blend amounts
no dead time, back ground, ... correction
both blends share the same “fate”

Isotope dilution approach




+




$$w_x = w_z \cdot \frac{m_{xy}}{m_x} \cdot \frac{m_z}{m_{zy}} \cdot \frac{R_y - R_{bx}}{R_{bx} - R_x} \cdot \frac{R_{bz} - R_z}{R_y - R_{bz}}$$

Quantification of proteins using ID




Species specific spike production

metals easily exchangeable such as Cu in SOD or CER or Fe in TRF




Species specific spike production

proteins with metals more strongly bound such as Fe in HGB



HGB quantification via characteristic peptides

- measurand of clinical importance: percentage of HBA₂ in blood
- IDMS for determination of HBA₂ and total HGB in reference materials






U-¹⁵N-HBA₀/A₂ (internal standards)
• added to sample in defined amounts

$$\text{percentage of HBA}_2 = [\text{HBA}_2] * 100 / [\text{total HGB}]$$

result 1 for HBA₀ or HBA₂
by quantifying **Hb-fragment 1** of β- or δ-globin

result 2 for „total HGB“
by quantifying **HGB-fragment 2** of α-globin

Protein quantification with ID-Raman




method	value g/dL Hb
ID Raman	16.20 ± 1.78
clinical lab	14.4 ± 0.9


S. Zakel, S. Wundrack, G. O'Connor, B. Guettler, R. Stosch, Journal of Raman Spectroscopy, 2013, 44 (9), 1246-1252

Comparison of HGB results

Method	Mass fraction $w / \text{g/kg}$	Uncertainty ($k=2$) $u_{\text{rel}} / \%$
certified value JCCRM 912-2M	132.1 ± 1.5	1.1
HiCN-method	130.5 ± 0.9	0.7
AHD-method	131.2 ± 1.5	1.1
IDMS	131.5 ± 5.6	3.9
triple SS-ICP-IDMS	133.1 ± 2.9	2.2
double SS-ICP-IDMS	135.4 ± 2.1	1.6
ICP-IDMS	136.0 ± 4.1	3.0
ID-Raman	136.0 ± 8.5	6.2



Transferrin in human serum (Ref. 1351)



Transferrin in human serum (Ref. 1351)

Sample: BCR®-637 human Serum (untreated Serum)

Instrumentation: HPLC-ICP-MS

Monitored elements: Fe (participants 1-3), S (participant 4)

4 Participants


Shipped and stored at -80 °C




Results:

Deviation between analysis of Fe or S

Problems with interferences in
untreated Serum



Outlook



Aims

- Development of methods for the **traceable quantification** of metals and metal containing biomolecules
- Production and characterisation of isotopically labelled spike materials
- Development of **new and accurate methods** for measuring peptide and protein biomarkers
- Characterisation of uptake, metabolism and transport of metals and metal containing biomolecules to the brain
- Facilitation of uptake of the technology and measurement infrastructure



**Physikalisch-Technische Bundesanstalt
Braunschweig und Berlin**

Bundesallee 100
38116 Braunschweig

Dr. Claudia Swart
Telefon: 0531 592-3150
E-Mail: claudia.swart@ptb.de
www.ptb.de

